NCT05262036进行中（未招募）不适用
The Effects of a Longevity Supplement on Skin Health, Blood Biomarkers and Mental Health
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Appearance of Fine Lines and Wrinkles
研究概览
简要总结
This study evaluates the use of an oral supplement to see if it can shift the function of the skin and the appearance of fine lines and wrinkles, its impact on biomarkers associated with aging, and its impact on mental health.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Female and male subjects
- •Subjects who are between the ages of 35 to
- •Subjects must be able to read and comprehend study procedure and consent forms
- •Must be willing to comply with all protocol requirements
- •Must be willing to have facial photographic images taken
排除标准
- •Women who have been pregnant in the last three months, currently pregnant, preparing to become pregnant during the study, or breastfeeding.
- •Individuals who have a history of smoking or chewing tobacco or vaping nicotine based product within the past year or if the pack-year history of smoking tobacco is greater than 5 pack-years.
- •Those that have undergone a change in hormone-based therapies such as, but not limited to, oral contraceptive pills or progesterone pills within the last 2 months. Progesterone releasing IUDs are considered hormone-based therapy. Spironolactone is not considered a hormone-based therapy.
- •Subjects who are unwilling or unable to comply with the requirements of the protocol.
- •Subjects who have a history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study in the opinion of the principal investigator.
- •Has a skin disease on the face that will interfere with image collection and assessment in the opinion of the investigator.
- •History of any significant chronic disease including endocrine, inflammatory, cardiovascular, renal, liver, gastro-intestinal, psychiatric, neurological, neoplastic, or metabolic disease for at least 90 days prior to screening. Clinical significance of active disease will be assessed by the Qualified Investigator to determine eligibility.
- •Subjects with or who have recently experienced traumatic injury, infections, or major surgery at the discretion of the Qualified Investigator.
- •Subjects who are likely to start taking drugs/medication on a chronic basis or that will undergo surgery during the trial.
- •Subjects engaged in donation or who were recipients of blood products within 90 days before the start of the study.
- •Subjects with alcohol use of more than 2 alcoholic beverages per day within the past month.
- •Subjects participated in a clinical trial with a medicinal, supplemental, nutraceutical or drug within the past two months prior to the first dose in the current study.
- •Use of lipid, cholesterol and/or blood-sugar lowering agents (e.g. statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, prescription-based nicotinic acid derivatives (e.g. niacin extended release), metformin, sulfonylureas, including fish oil). If participants take fish oil supplements, they will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
- •Subjects using anti-inflammatory drugs on a chronic basis (e.g. aspirin, ibuprofen, diclofenac, celecoxib, etc).
- •Subjects using supplements or substances present in formulation (malate, fisetin, glucosamine, alpha ketoglutaric acid, glycine, theanine, Rhodiola rosea, hyaluronic acid, ginger extract, pterostilbene, lithium). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
- •Subjects using supplements or substances similar as those used in the formulation (e.g. resveratrol (similar to pterostilbene) or quercetin (similar to fisetin)). Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
- •Subjects taking NAD boosters, like NMN, nicotinamide riboside (NR), high-dose niacin (nicotinic acid), high-dose vitamin B3, high-dose nicotinamide (niacinamide) within 21 days before the start of the trial. Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
- •Subjects taking supplements or drugs or nutraceuticals to improve skin, such as hyaluronic acid, collagen, chondroitin, glucosamine. Participants will be asked to stop taking these supplements 21 days before the start of trial and during the trial.
- •Subjects with clinically significant abnormal laboratory results at screening.
结局指标
主要结局
Appearance of Fine Lines and Wrinkles
时间窗: 6 months
Fine lines and wrinkles measured by high resolution photography (BTBP Clarity Pro) to measure wrinkle severity (combines depth and width). Measured by computer calculation.
次要结局
- Appearance of facial pigmentation(6 months)
- Skin elasticity(6 months)
- Hemoglobin A1c(6 months)
- Subjective skin health survey(6 months)
- Fasting lipids(6 months)
- Ultra-sensitive CRP(6 months)
- Appearance of facial redness(6 months)
- Skin hydration(6 months)
- Appearance of facial texture(6 months)
- Blood pressure(6 months)
- Mental health survey(6 months)
- Epigenetic signals(6 months)
研究者
Raja Sivamani, MD MS AP
Integrative Dermatologist
Integrative Skin Science and Research
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and WomenSkin AgingNCT06083402Natals, Inc. dba Ritual63
已完成
1 期
Natreon Healthy Skin Study - PrimaVie SupplementHealthyNCT02762032Ohio State University45
尚未招募
1 期
Research on skin improvement by daily drinking of high-quality green tea (Matcha) - search for active ingredientshealthy adultsJPRN-UMIN000049845Kyoto Prefectural University of Medicine90
尚未招募
不适用
Effects of an Oral Herbal Supplement on Skin Aging, Hydration, and ElasticityPhotoagingNCT06146140Integrative Skin Science and Research36
已完成
不适用
Improvement effect on skin condition by long-term use of anti-wrinkle cosmetic "OG Hydrating Serum"Healthy adult femaleJPRN-UMIN000045257Japan Clinical Trial Association28